focus -WSS

focus

author：leisure time 2025-08-26 23:44:24 - browse：26966

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： FDA's Woodcock to retire early next year

hotspot

WSS

Indictment alleges Trump's ex

Hospitals look to new technology to keep health care workers safe

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Idaho college killings prosecutors challenge defense's grand jury claims

Biden administration begins canceling student loan debt for 804,000 borrowers

knowledge

focus

entertainment

Medical leaders decry Supreme Court decision on affirmative action

Anthos stroke drug appears safer than common blood thinner

United colonoscopy coverage change 'may cost lives,' doctors say

Surge in Apellis stock fueled by confidence in safety of its eye drug

Sports medicine is finally prioritizing gender equality

Novo Nordisk touts Wegovy study, but still struggling with supply

How to save PrEP access — and even expand it

Megan Rapinoe shares emotional post following US Women's World Cup exit

How one medical school became remarkably diverse

Novo Nordisk touts Wegovy study, but still struggling with supply

hotspot

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Morphosys mixed study results for blood cancer drug

Megan Rapinoe shares emotional post following US Women's World Cup exit

Congress must reauthorize a committee to support older Americans

Gain of function research would be limited under House proposal

Surge of respiratory disease in China has likely explanation

hotspot

knowledge

focus

Wikipedia